Interestingly, pharmacological studies indicate that the administration of rimonabant, a CB1 antagonist, increases symptoms of depression and anxiety in healthy individuals [57] and that the effects of conventional antidepressant drugs depend on the eCB signaling [58]. This evidence concerns the gene CNR1 and depressive symptom measurement.